Retatrutide: Next-Generation Triple Agonist Guide

Retatrutide represents the next generation of incretin-based weight management medicines. Unlike Semaglutide (GLP-1 only) or Tirzepatide (dual GIP/GLP-1), Retatrutide activates three receptors — GLP-1, GIP, and glucagon — adding energy expenditure and hepatic fat metabolism effects to appetite suppression.

Why the Third Pathway Matters

Glucagon receptor activation may increase energy expenditure and support liver fat reduction — effects not typically seen with single or dual agonists alone. This makes Retatrutide relevant for advanced clinical programs with experienced practitioner oversight.

Clinical Considerations

• Reserved for established clinic protocols with documented monitoring
• Requires careful titration due to multi-pathway activity
• Available as 36mg / 3ml vial and pre-filled pen in the Master Pharm formulary
• Patients should understand this is an advanced therapy within professional programs